Susquehanna International Group’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.62M Sell
51,500
-26,700
-34% -$770K ﹤0.01% 6663
2025
Q4
$1.94M Buy
78,200
+1,700
+2% +$34.1K ﹤0.01% 5722
2025
Q3
$1.24M Buy
76,500
+60,900
+390% +$864K ﹤0.01% 6825
2025
Q2
$205K Sell
15,600
-116,900
-88% -$1.69M ﹤0.01% 11170
2025
Q1
$2.92M Buy
132,500
+11,500
+10% +$302K ﹤0.01% 4709
2024
Q4
$3.23M Sell
121,000
-138,800
-53% -$4.42M ﹤0.01% 4346
2024
Q3
$6.93M Buy
259,800
+225,000
+647% +$4.48M ﹤0.01% 3106
2024
Q2
$627K Buy
+34,800
New +$607K ﹤0.01% 7724
2023
Q3
Sell
-15,000
Closed -$116K 12261
2023
Q2
$116K Buy
+15,000
New +$127K ﹤0.01% 10825

Other funds holding EWTX

Susquehanna International Group's EWTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Edgewise Therapeutics (EWTX) stake by 62% in Q1 2026, selling an estimated $1.26M and leaving 26,674 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #8350.

Susquehanna International Group first reported a position in EWTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $5.35M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Susquehanna International Group held 26,674 shares of Edgewise Therapeutics worth $840K as of Q1 2026.
  • Susquehanna International Group sold 43,522 Edgewise Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Edgewise Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8350 holding.
  • Susquehanna International Group first reported a position in Edgewise Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Susquehanna International Group's Edgewise Therapeutics position peaked at $5.35M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.